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Abstract
Intestinal barrier integrity is a prerequisite for homeostasis of mucosal function, which is balanced to maximise absorptive capacity, while
maintaining efficient defensive reactions against chemical and microbial challenges. Evidence is mounting that disruption of epithelial barrier
integrity is one of the major aetiological factors associated with several gastrointestinal diseases, including infection by pathogens, obesity and
diabetes, necrotising enterocolitis, irritable bowel syndrome and inflammatory bowel disease. The notion that specific probiotic bacterial
strains can affect barrier integrity fuelled research in which in vitro cell lines, animal models and clinical trials are used to assess whether
probiotics can revert the diseased state back to homeostasis and health. This review catalogues and categorises the lines of evidence available
in literature for the role of probiotics in epithelial integrity and, consequently, their beneficial effect for the reduction of gastrointestinal disease
symptoms.
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The human intestine contains a dense and complex community
of microbes, and many representatives permanently inhabit this
niche(1,2). In addition to the resident microbiota, various
bacteria transiently pass through the intestine as a consequence
of ingestion – for example in fermented food products, or as
supplements containing probiotics(3,4). The latter are defined as
‘live micro-organisms that, when administered in adequate
amounts, confer a health benefit on the host’(5,6). In the
intestinal tract, a single layer of epithelial cells forms a physical
barrier between the intestinal lumen, the lamina propria and
the mucosal-associated lymphoid tissue. In addition, mucus
secreted by goblet cells in the epithelium serves to spatially
compartmentalise the bacteria to the lumen and prevent bac-
terial colonisation of the epithelium(7–9). Mice lacking Muc2, the
major secreted mucin in the intestine, develop spontaneous
colitis demonstrating its important barrier function(10). Mucosal
Ig and antimicrobial peptides (AMP) and proteins secreted by
the epithelial cells serve to enhance the barrier function of
the epithelium through immune exclusion and killing of
bacteria(11). Moreover, in mucus-deficient mice, the ileal region
of the intestine appears to be protected from excessive
inflammatory responses by activation of epithelial repair
and barrier maintenance pathways through the IL-22-STAT
regulatory axis(12).
The first direct evidence for the role of epithelial integrity in
preventing intestinal inflammation came from a chimeric mouse
model in which parts of the small bowel epithelium expressed
N-cadherin instead of E-cadherin, thereby disrupting the
E-cadherin homotypic interactions that help maintain junctional
integrity(13). The regions of the intestine expressing N-cadherin
were more permeable than the areas expressing E-cadherin and
developed focal lesions because of inflammation. Since then,
studies in several different knockout mice have shown that defects
in the pathways maintaining epithelial integrity, epithelial stress
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responses or the regulation of mucosal immune responses lead to
barrier destruction and colitis triggered by bacterial antigens and
microbe-associated molecular patterns (MAMP)(14–19).
Despite the role of commensal MAMP in triggering inflammatory
responses, homeostasis is not maintained by a ‘passive’mechanism
of lack of recognition. In contrast, Toll-like receptor (TLR) activation
by commensal bacteria was shown to play a crucial role in the
recovery from epithelial damage induced by dextran sodium sul-
phate (DSS)(20–24). Similarly, mice with a knockout of NEMO
(ikappa kinase γ), an activator of NF-κB, develop spontaneous
colitis because of the role of NF-κB in inducing epithelial repair
and innate effector mechanisms in the intestine(18). TLR signalling
and in particular TLR-2 signalling and protein kinase C (PKC)α
and PKCδ activation have also been implicated in tight-junction
(TJ) function modulation and epithelial permeability(25).
A limited number of studies report the impact of probiotics on
barrier integrity in (healthy) human volunteers, although several
plausible direct and indirect mechanisms of bacterial modula-
tion of barrier function have been postulated (Fig. 1). For
example, Gotteland et al.(26) evaluated the impact of con-
sumption of Lactobacillus rhamnosus GG in healthy human
volunteers upon epithelial barrier challenge by treatment with
the nonsteroidal anti-inflammatory drug indomethacin. The
authors reported that the consumption of live L. rhamnosus GG
protected the integrity of the gastric mucosal barrier, but had no
effect at the intestinal level(26), highlighting the differences in




































Fig. 1. Direct and indirect mechanisms by which commensals or probiotics can antagonise pathogens. Graphical display of exemplary direct (a) and indirect (b)
mechanisms of barrier function modulation by bacterial (probiotic) interaction. (a) Direct mechanisms of barrier function modulation by interaction of commensals and
probiotics. Bacteria can compete with enteric pathogens by competition for carbohydrates depending on the diet(227). A probiotic strain of Lactobacillus salivarius
UCC118 produces a bacteriocin in vivo that can significantly protect mice against infection with the invasive foodborne pathogen Listeria monocytogenes(36). In diverse
Bacteroides species, a type VI secretion system (T6SS) mediates cell-contact-dependent mechanisms of inter-bacterial antagonism via the export antibacterial
proteins(228). Probiotics have been shown to inhibit the colonisation of pathogens through competition for common receptors of adhesion(48). (b) Indirect mechanisms of
pathogen antagonism. Recognition of microbe-associated molecular patterns by host pattern recognition receptors such as TLR and NLR activate immune defences
and protect against infection. TLR signalling induces expression of defensins in enterocytes and antimicrobial factors in Paneth cells via the myeloid differentiation
primary response 88 (MYD88) activation of NF-κB leading to the production of antimicrobial peptides. Similarly, nucleotide-binding oligomerisation domain 2 (NOD2)
recognition of bacterial peptidoglycan induces cryptdin expression by Paneth cells. Sensing of an unknown signal from commensal microbes stimulates type 3 innate
lymphoid cells (ILC) to secrete IL-22, which signals through the receptor (IL-22R) on intestinal epithelial cells to increase expression of the fucosyltransferase (FUT),
mucin expression and antimicrobials, including regenerating family member 3 (Reg3) proteins. Segmented filamentous bacteria (SFB) closely associate with the ileum
epithelium and stimulate maturation of the B- and T-cell compartments leading to enhanced IgA production by B cells and serum amyloid A (SAA)-dependent T helper
17 (Th17) cell differentiation. Th17 cells produce inflammatory cytokines and IL-22, which stimulate innate immune defence mechanisms to fight off infections.
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physiology of the epithelial barrier in different locations of the
gastrointestinal tract. Karczewski et al.(25) performed TJ staining
in duodenal samples obtained from healthy volunteers after
perfusion with Lactobacillus plantarum WCFS1, revealing that
the TJ localisations of scaffold protein ZO-1 (zonula occludens-1,
also known as tight junction protein-1) and the transmembrane
protein occludin were significantly increased by the interaction
with this bacterium. Subsequently, these authors showed that the
same strain conferred protection against chemically induced
barrier disruption in an in vitro Caco-2 cell line model, involving
a TLR-2-dependent signalling pathways(25). These studies
imply that probiotic interventions are a plausible approach to
enhance epithelial barrier function in human subjects, possibly
in a location-specific (gastric v. intestinal) manner.
Increased mucosal permeability and loss of epithelial integ-
rity are recognised to play a role in the pathophysiology of a
variety of (gastrointestinal) disorders, including the challenge
by intestinal pathogens, inflammatory bowel disease (IBD),
irritable bowel syndrome (IBS), obesity and the metabolic
syndrome and necrotising enterocolitis (NEC). One hallmark of
all these disorders is the involvement of a compromised barrier
function in the pathophysiology. Thus, many probiotic studies
have been targeting patient populations or animal models for
human diseases, to evaluate their protective capacity on clinical
parameters, including barrier function. Below, we review
the state of the art of these approaches and propose future
strategies aiming to further substantiate our understanding of
the mode of action of probiotics.
Pathogen challenges to the barrier
The mucosal barrier can be challenged by encounters with
bacterial or viral pathogens; however, for obvious ethical
reasons, it is not trivial to perform well-controlled human
infection studies. As an alternative, attenuated pathogenic
bacteria, which were developed as oral vaccines, have been
used for experimental challenge studies in humans(27). The
attenuated bacterial pathogens generally lead to mild diarrhoea,
offering a model system for controlled enteric pathogen
challenge studies in human individuals(28,29). However, it
remains unclear whether these (more or less) attenuated enteric
pathogens have similar effects on the mucosal barrier function
as compared with the pathogenic strains they were derived
from. Nevertheless, these models have been used to study the
protective capacity of probiotics and other dietary ingredient
interventions, with generally poor success rates for probiotics in
the amelioration of diarrhoea symptoms(30,31). Several studies
have evaluated the potential of probiotics in eradication therapy
of Helicobacter pylori(32) and the prevention of rotavirus-caused
diarrhoea in children(33,34), although with a variable outcome.
Rodent models offer more flexibility and control for challenge
studies with enteric pathogens and in examining the potential of
probiotics to affect the efficacy of infection. In this area, various
rodent in vivo(35) infection models have demonstrated that
probiotics can attenuate the severity of infection caused
by several gastrointestinal pathogens, including H. pylori,
Citrobacter rodentium, Listeria monocytogenes and Salmonella
typhimurium(36–41). In many cases, the molecular mechanisms
behind the positive effects remain unknown. Various mecha-
nisms of probiotic action have been postulated that can explain
their positive effects in enteropathogen infection models,
although in only few of these scenarios there is a direct and
pivotal role established for their effect on mucosal barrier
function(35).
The presence of commensal bacteria can inhibit the efficacy
of enteropathogens via ‘colonisation resistance’, which
encompasses a variety of molecular mechanisms involving
microbe–microbe and/or microbe–host interactions(42,43).
Ingested probiotic bacteria may modulate the endogenous
microbiota composition by competing for (micro-)nutrients
and/or the production of (secondary) metabolic products,
thereby modulating the endogenous microbiota composition
and/or activity, which may affect colonisation resistance and
risk or severity of enteric pathogen infection(43).
Probiotics can produce antimicrobial compounds that may
have an impact on the pathogenic bacteria directly, or via their
effects on the endogenous microbiota. For example, Lactobacillus
reuteri can produce reuterin, a secondary metabolite with broad-
spectrum antimicrobial activity that can modulate the microbiota
composition, as well as directly inhibit enteric pathogens(44).
Alternatively, probiotics may produce broad- or narrow-spectrum
bacteriocins, which are small ribosomally synthesised peptides
that inhibit the growth of other bacteria(45), which may affect
enteric pathogens directly. A well-developed example of such
bacteriocin is the class II bacteriocin Abp118 that is produced
by Lactobacillus salivarius UCC118 and effectively inhibits
L. monocytogenes infection and barrier disruption in vivo in a
mouse model(36). Probiotics may also directly compete for
mucosal adherence sites with pathogenic bacteria, a mechanism
termed competitive exclusion(46). However, in many cases the
mechanism of anti-adherence remains unclear. A mannose-
specific adhesin of L. plantarum has been identified that is
proposed to play a role in the competitive exclusion of FimH-
dependent adhesion of enteropathogenic Escherichia coli
(EPEC), or other mannose adhesion-dependent enteric pathogens
(e.g. S. typhimurium)(47,48). Besides such direct competitive epi-
thelial binding, other mechanisms may also underlie competitive
exclusion such as the degradation of mucosal surface receptors
by secreted enzymes, or the production of receptor analogues or
bio-surfactants. However, in light of recent insights about the
mucus barrier, the in vivo relevance of in vitro studies evaluating
the inhibition of pathogen adherence to cell lines might be
questioned. This is because of the fact that commensal contact
with epithelial cells is very limited and hardly observed in vivo,
because of the presence of a physical mucus barrier. In the colon,
a thick firm layer of mucus overlays the epithelium and is devoid
of bacteria, despite the large numbers residing in the lumen(49). In
the small intestine, the mucus layer is thinner, but bacteria are
rarely seen in contact with the epithelium(8), the exception being
segmented filamentous bacteria in mice that have an atypical
and intimate association with enterocytes(50). In contrast to
gram-positive probiotic strains, several enteric gram-negative
pathogens possess flagella, which propel them through mucus.
The probiotic E. coli Nissle (EcN) is flagellated and motile and
thus has increased potential to inhibit pathogen adherence and
invasion. EcN has been shown to inhibit invasion of various
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epithelial cell lines by Yersinia enterocolitica, Shigella
flexneri, S. typhimurium and L. monocytogenes, via secretion
of an unidentified factor rather than competition for
receptors(51).
Many pathogens influence barrier permeability through pro-
duction of toxins that disrupt TJ and/or cause increased secre-
tion or decreased absorption of fluids and electrolytes(52,53).
Bifidobacterium breve strain Yakult and Bifidobacterium
pseudocatenulatum DSM20439 have been described to inhibit
the expression of Shiga toxin in enterohemorrhagic E. coli
(EHEC) 0157:H7 strains in vitro, as well as in vivo in a mouse
infection model(54). This effect appears relatively unspecific, as
subsequent work illustrated Shiga toxin expression inhibition in
EHEC in vitro by fifteen different probiotics, depending on
their capacity to produce organic acids(55). A more specific
mechanism has been proposed for probiotic yeast
Saccharomyces boulardii that secretes a protease that can
degrade Toxin A that is produced by Clostridium difficile(56).
Lesions in the epithelium can also be caused by cytoskeleton
rearrangements induced by colonisation and invasion of
enteropathogens. In vitro, these virulence mechanisms cause a
drop in transepithelial electrical resistance (TEER) of epithelial
cell monolayers. Lactobacillus strains of intestinal origin have
been shown to inhibit pathogen-induced disruption of epithelial
integrity. Lactobacillus acidophilus LB(57) and Lactobacillus
helveticus R0052(58) have been shown to antagonise the
cytoskeleton rearrangements caused by EPEC in vitro.
Similar studies have shown that L. helveticus strain R0052(58)
L. plantarum 299v(59,60) and Lactobacillus casei DN-114 001(61)
reduce the drop in TEER caused by infection of T84 intestinal
cells with EHEC and EPEC.
More recently, the concept of indirect pathogen antagonism
arose by the recognition that microbial colonisation can sti-
mulate innate and adaptive immune responses in the intestinal
mucosa(11,62). Stimulation of innate receptors expressed in the
epithelium can enhance the production of inducible anti-
microbials such as epithelial β-defensins and members of the
antimicrobial C-type lectins in the gut(63). Indeed, colonisation
of germ-free mice and the expansion of bacteria after weaning
caused an increased regenerating family member 3 (Reg3)
production(64,65). However, some studies reported no change in
production of defensins by commensal colonisation of the
gut(66,67), which may be due to differences in the regulatory
control of certain AMP. Several studies using epithelial cell lines
in vitro have demonstrated the capacity of probiotics to
differentially regulate defensins(68–71). Apart from the induction
of AMP, probiotics might affect the mucus barrier. This could be
through bacterial interaction with innate cells in the mucosa
producing cytokines (e.g. IL-22(11), IL-8(72)) that can increase
the expression of specific mucin genes. For example, in vitro
studies have shown that adherent Lactobacillus spp. can
stimulate MUC3 expression in human intestinal epithelial
cells and thereby inhibit EPEC adherence(72–74). Analogously,
lipopolysaccharide (LPS) can stimulate expression and
secretion of MUC5AC and MUC5B(75), and thereby enhance
mucus barrier function(75). These examples illustrate the
potential of probiotics to enhance epithelial and mucus barrier
functions, thereby protecting the host against enteric pathogens.
Obesity and diabetes
Low-grade inflammation, and in particular endotoxaemia
(i.e. relatively high amounts of gut microbiota-derived LPS in
plasma), has been identified as a factor involved in the onset
and progression of metabolic diseases associated with obesity
(insulin resistance, type 2 diabetes) in human and rodent
models(76–79). A high fat content in the diet and changes in
barrier function are considered to be important factors in
endotoxaemia(80,81). Several studies have shown that both diet-
induced and genetic obese and type 2 diabetic mice displayed
changes in gut microbiota(76,77,82–86). Among the reduced
abundance bacterial groups were the bifidobacteria(87), which
in mice has been associated with reduced intestinal LPS levels
and improved mucosal barrier function(88–92). These observa-
tions are in agreement with the reduction of metabolic endo-
toxaemia, gut barrier dysfunction and inflammatory disorders
that could be achieved in mice by prebiotic supplementation,
which restored the bifidobacterial abundance in the intestinal
microbiota(76,83,93,94). However, the precise mechanism under-
lying these health improvements remain unclear, and may not
be entirely attributed to Bifidobacterium spp.(95). Although
rodent models have revealed the impact of prebiotic
supplementation on obesity, type 2 diabetes and gut barrier
function(96–99), only few studies have been conducted in
human obese and type 2 diabetic populations(100–102). One of
these studies described enhanced weight loss and improved
glucose regulation in obese adults who consumed fructo-
oligosaccharide (FOS) supplements (21 g/d) for 12 weeks,
which was tentatively associated with FOS-induced suppressed
ghrelin and enhanced peptide YY production(100). The second
study showed that long-term synbiotic supplementation
(Bifidobacterium longum and FOS) in sixty-six overweight
non-alcoholic steatohepatitis patients could reduce endotox-
aemia, insulin resistance, steatosis and several metabolic and
inflammatory parameters(101). Besides these studies using
prebiotic and synbiotic supplementation in rodent models and
human populations, several studies have reported on the ben-
eficial impacts of probiotics on obesity and type 2 diabetes in
rodent models. In many of these studies, diet-induced obesity
models were used to induce metabolic dysfunction in the
animal models to subsequently address the possible health
beneficial role of probiotic supplementation(103). In such
a setting, various lactobacilli were shown to positively
affect various metabolic disorder parameters. For example,
Lactobacillus gasseri BNR17 reduced body weight and fat mass
development in overweight rats(104,105), whereas in high-fat-
diet-induced obese mouse models L. plantarum 14 supple-
mentation was shown to reduce the mean adipocyte size(106)
and Lactobacillus paracasei F19 could induce a reduction of
total fat mass and plasma TAG possibly via a mechanism
involving angiopoietin-like factor 4(107). In contrast, L. acid-
ophilus NCDC supplementation in diet-induced obese mice did
not induce any significant changes in body fat composition
and/or liver and muscle fat content(108). Analogously, L. casei
Shirota did not affect fat mass and body weight in diet-induced
obese mice but, nevertheless, did induce a reduction of insulin
resistance and endotoxaemia, illustrating that the impact on gut
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barrier function and glucose regulation can be elicited by
mechanisms that are independent of body weight and fat mass
development(109). A few human intervention studies were also
performed, including a study that suggests that specific Lacto-
bacillus strains have an impact on body fat, weight and meta-
bolic disorders. For example, the ingestion of L. gasseri
SBT2055 for 12 weeks reduced fat-mass gain, body weight,
waist:hip ratio in overweight subjects compared with pla-
cebo(110), an effect recently confirmed by the authors(111). Jung
et al.(112) have shown that the ingestion of Lactobacillus gasseri
BNR17, a strain showing beneficial effects in rodents, reduced
weight and waist and hip circumference after 12 weeks of
treatment. Sanchez et al. have observed that supplementation
with L. rhamnosus CGMCC1.3724 (1·6× 108 colony-forming
units (CFU) of the strain per capsule with oligofructose and
inulin) helped to lose more weight in women after the first
12 weeks, whereas it has no effect in men. Interestingly, while
women in the placebo group regain weight during the weight-
maintenance period, opposite changes were observed in
women from the treated group who continued to lose body
weight and fat mass. Finally, another study showed that the
perinatal modulation of the gut microbiota by L. rhamnosus GG
reduces excessive weight gain during the first years of life in
children(113), thereby suggesting that perinatal intervention may
also be beneficial for the infants.
Several studies described a positive impact of Lactobacillus
spp. supplementation on diet-induced metabolic disorders,
including improved intestinal barrier function and reduced
endotoxaemia. However, a recent study showed that in 3-week-
old mice the high-dosage supplementation with Lactobacillus
ingluviei (4× 1010 CFU) led to increased overall weight gain, as
well as total liver weight, while not affecting fat mass despite
increased transcription levels of the lipogenic markers (PPARγ
and sterol regulatory element-binding protein 1c) in the gonadal
fat mass(114). The variability in the results obtained in these
models imply that both the specific rodent model (age of the
animals and the mode by which metabolic disorders are
induced) and the choice of Lactobacillus spp. could have a major
impact on the outcomes of these interventions. Nevertheless, in
adult animals there are multiple indications that lactobacilli
may positively affect different metabolic disorder parameters,
including compromised barrier function and inflammatory status.
Analogous to the lactobacilli, bifidobacteria have also been
evaluated for their capacity to improve metabolic disorders in
diet-induced rodent models for obesity and diabetes(103). For
example, in a high-fat-diet-induced obesity model in rats, a
mixture of three Bifidobacterium strains (B. pseudocatenulatum
SPM 1204, B. longum SPM 1205 and B. longum SPM 1207) was
shown to reduce body weight and adiposity, but it also reduced
cholesterol (total, HDL-cholesterol and LDL-cholesterol), TAG,
glucose, leptin and hepatic enzyme (aspartate aminotransferase,
alanine aminotransferase and lipase) levels in plasma, suggesting
beneficial effects of this strain mixture in high-fat-diet-induced
obesity and type 2 diabetes(115). In a similar model, B. longum
supplementation could compensate the decreased endogenous
Bifidobacterium abundance induced by the high-fat diet, and led
to reduced body weight gain, fat mass, insulin resistance, systolic
blood pressure, as well as lowered metabolic endotoxaemia, and
IL-1β and intestinal myeloperoxidase levels in plasma. The authors
proposed that these effects might be mechanistically linked to
enhanced barrier function induced by B. longum supplementation
via increased expression of intestinal REG-family proteins(116).
Notably, a recent study illustrated that in high-fat-diet-induced
obese mice, the translocation of gram-negative Enterobacteriaceae
to adipose tissue and blood was increased, which was accom-
panied by elevated inflammation status. This ‘metabolic bacter-
emia’ could be suppressed by dietary supplementation with
Bifidobacterium animalis subsp. lactis 420, which not only nor-
malised inflammation status but also corrected insulin sensitivity
and hyperinsulinemia(117). Intriguingly, this Bifidobacterium
strain was also shown to competitively exclude the binding of
pathogenic bacteria to the mucosa(118) and improve TJ
integrity(119) in vitro, again pointing towards enhanced intestinal
barrier function as the compensatory mode of action.
More recently, the role of another putative beneficial
bacterium, namely Akkermansia muciniphila, has been dis-
covered. Obese and diabetic mice treated with A. muciniphila
exhibit a reduced body weight and fat mass gain, a reduced
inflammation and metabolic endotoxaemia upon high-fat-diet
feeding. Although the overall mechanisms are not fully eluci-
dated, this bacterium reinforced the gut barrier function by
increasing the production of specific endocannabinoids with
anti-inflammatory properties, Reg3γ, and increased the mucus
layer thickness(120,121). Taken together, a variety of rodent
model studies indicate that probiotics may elicit beneficial
impacts in metabolic disorders associated with obesity and
diabetes. Moreover, several studies indicate that these effects
may be exerted by a postulated role of probiotics in modulation
of the intestinal barrier function, albeit via unknown molecular
mechanisms. Importantly, very few studies have evaluated
whether similar effects can be achieved in human studies,
marking a major caveat in our understanding of the possibilities
of probiotic benefits in human obesity and diabetes.
Necrotising enterocolitis
NEC is an acute inflammatory process in the immature intestine,
which affects 5–10% of very low birth weight infants and results
in high mortality, heavy complications and invalidating
sequelae(122). Several randomised clinical trials indicate a
protective effect of probiotics in the prevention on NEC. Despite
recent critical reviews and meta-analyses(123–127) that support
significant reduction in the incidence of severe NEC and mortality
in preterm infants by probiotics, medical experts hesitate to
recommend the routine use of a specific probiotic treatment
and await large and well-designed safety and efficacy trials to
complement the currently available pooled analysis of relatively
small trials that use different probiotic strains(126,127). Nevertheless,
most experts agree on the potential of some probiotic strains to
reduce the incidence and severity of NEC. In previous papers, it
has been extensively discussed that immaturity of the intestinal
barrier is amongst the major aetiological factors of NEC(128–134)
and may be modulated by probiotic administration.
Most probiotic trials in preterm infants have focused on the
impact on intestinal colonisation as measured by faecal
microbiota composition analyses(135–142). These studies have
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illustrated that a variety of (mixtures of) probiotic strains or
synbiotics can reduce the levels of potential pathogenic bacteria
and yeast species in the faecal microbiota, which could con-
tribute to the reduction of incidence and severity of NEC. An
alternative scenario proposed that some probiotic strains such
as L. reuteri ATCC 55730 could play a role in accelerating the
gastrointestinal motility(143) thereby preventing intestinal over-
growth, which is a proposed NEC risk factor.
Only two clinical trials that used the probiotic strain
Bifidobacterium lactis CNCM I-3446 have addressed other
components of the preterm barrier function. One of these
studies demonstrated that this probiotic induced a faster
decrease of intestinal permeability levels and, not surprisingly,
an increased relative abundance of faecal bifidobacteria(144).
Although this small study was not powered to assess the impact
on NEC, three infants developed the disease within the placebo
group, whereas none developed NEC in the probiotic group. In
a separate study that used the same probiotic, the expected
bifidogenic effect was confirmed and was accompanied by
reduced counts in faecal samples of potentially pathogenic
bacteria (e.g. clostridia and enterobacteria(145)), which may be
related to accompanying increased faecal SCFA levels and
lower faecal pH(150). Notably, this study also reported
decreased calprotectin (marker for intestinal inflammation) and
increased serum IgA levels in faecal samples(146), supporting
the proposed impact of this probiotic on barrier function either
directly or via the decreased relative abundance of pathogenic
bacterial groups.
Most studies that support a role of probiotics in the accele-
ration of appropriate barrier function establishment in the
immature intestinal tract have been generated in neonatal
animal models using immature pigs, rabbits or rats to mimic the
preterm infant barrier and the NEC-associated inflammatory
conditions. The available data obtained in such models support
that some probiotic strains can reduce the incidence and/or
severity of NEC by modulating diverse components of the
intestinal barrier. These studies report favourable effects on the
diversity of the commensal microbiota(147–149), including
reduced luminal and mucosal colonisation, as well as translo-
cation to extra-intestinal organs of pathogenic bacteria(150–152).
Barrier integrity improvements measured in these models
include a decreased permeability to small solutes(153), macro-
molecules(147,153–156) and endotoxin(157). Moreover, in these
models, the mucosal expression of various factors involved in
barrier function regulation and maintenance could be normal-
ised by probiotic supplementation, including TLR4(158)
and TLR9(159), mucin and trefoil factor (TFF)(160) and anti-
microbial protein and peptides(161). Probiotics were also shown
to enhance enterocyte proliferation and migration(148), to
reduce apoptosis and promote epithelial cytoprotective
responses(160,162,163), to improve the expression of the enter-
ocyte injury markers intestinal-type and liver-type fatty-acid-
binding proteins (I-FABP and L-FABP)(164), to restore the
expression and localisation of TJ and adherens junction
proteins(160) and to restore the thickness of the intestinal
mucosal and muscle layers(164). Most of these trials do not
inform about the specificity of the probiotic preparation related to
their gut barrier effects, as they focused on the effect of one single
probiotic or a probiotic mixture. However, when phylogenetically
close strains were compared, they generally differentially modu-
lated both intestinal inflammation and barrier outcomes(148,158,165).
In line with this, a trial in preterm piglets fed a probiotic
blend (L. paracasei ATCC55544, B. animalis DSM15954 and
Streptococcus thermophilus DSM15957) either alive or inacti-
vated by γ-irradiation reported not a decrease but an increase in
the rate of NEC in the probiotic-treated animals. This was
associated with impaired paracellular permeability in the group
fed dead probiotics, and with exacerbated expression of
proinflammatory cytokines and reduced microbiota diversity in
the group fed the live probiotic blend(166). To the best of our
knowledge, similar results have never been reported in preterm
infants and, although cases of sepsis due to probiotic adminis-
tration have been occasionally described in preterm(167) and
immunocompromised patients(168), these cases remain rare. As
discussed by the authors, the results in the piglet study may
be explained by experimental bias and would require con-
firmation(166). Nevertheless, this study fuels safety concerns of
probiotic applications in the highly sensitive preterm infant
population, and supports the request for larger-scale safety and
efficacy studies mentioned above.
Taken together, the evidence in neonatal animal models
supports that probiotics can strengthen a variety of the imma-
ture gut barrier components, which can contribute to reduced
incidence and/or severity of NEC. However, only few human
studies evaluated barrier function modulation by probiotics in
preterm infants and largely focused on their impact on micro-
bial colonisation and microbiota composition. Most of these
studies reported reduced pathogen loads in the developing
preterm intestine upon probiotic administration, and some of
them accelerated maturation of specific barrier components.
The preclinical data suggest probiotic specificity on their barrier
modulatory activity and therefore the need for a careful
evaluation of each probiotic preparation.
Overall, current knowledge could translate into recom-
mended routine use of specific probiotics in preterm infants,
provided that large-scale and well-designed multicentre
validation studies confirm their efficacy and safety.
Irritable bowel syndrome
IBS is a gastrointestinal disorder characterised by the association
between recurrent abdominal pain/discomfort and a change in
stool consistency or frequency. IBS has been classified
according to dominant symptomatology in subgroups as con-
stipation-predominant, diarrohea-predominant and mixed-type
IBS. The worldwide prevalence is estimated to be 10–20%,
thereby causing an important health and social burden with
substantial medical costs(169,170). Increased visceral perception
and deregulated mucosal immune responses are characteristics
of IBS directly related to deterioration of intestinal barrier
function. After an initial report from Finland(171), increasing
evidence emerged on distinct and various alterations in gut
microbial composition in subgroups of IBS patients around the
globe(171–175). Separate analysis of the faecal and mucosa-
associated microbiome in IBS revealed specific patterns and
correlates with mucosal lymphocyte phenotypes(176). Although
98 P. A. Bron et al.
the scientific debate is ongoing, this suggests that at least in
subpopulations of the IBS patient pool the gut microbiota is
likely contributing to disease symptoms through an altered
fermentation process, a harmful modulation of enteric sensori-
motor function, an impaired intestinal barrier function,
sustained immune activation without macroscopic signs of
inflammation and a harmful modulation of the brain–gut
axis(177–180). Moreover, specific probiotics have demonstrated
effects on barrier function(25), suggesting these bacteria might
have a beneficial impact on IBS symptom scores. Mostly,
in vitro and ex vivo cell culture(181,182), as well as animal models
such as mice(181–183) and rats(184,185), have been used in which
epithelial barrier integrity is experimentally disrupted before the
addition of (mixtures of) a probiotic strain. Several of these
studies demonstrated alleviation of IBS-like symptoms in animal
models and importantly also showed restoration of barrier
function, which was likely due to the enhanced expression of TJ
proteins such as occludin, E-cadherin and claudin-1 observed in
the probiotic-treated groups. Probiotics could be a promising
treatment option in IBS, and several, often small-scale, random-
ised clinical trials have been performed with various strains or
mixtures of strains. Overall, the results of these trials are difficult
to interpret, because of the use of different strains and combi-
nations thereof, as well as limitations in the study designs(186).
Nevertheless, the current consensus in the scientific community is
that there is a beneficial potential of the administration of specific
probiotics strains in IBS, but that more robust clinical trials are
required(187–190). Particularly, lactic acid bacteria have been
selected as promising probiotic candidates in the treatment of
IBS(191). Although the concept seems attractive, it is not well
established that a multi-strain or multi-species probiotic therapy
would be preferable to single-strain administration. Irrespective of
the outcome of these trials, it remains to be established whether
eventual beneficial effects of probiotic supplementation in IBS are
mediated through effects on barrier function.
A further area that deserves attention is the combination of
selected non-digestible polysaccharides and other prebiotic
compounds with specific probiotic strains (denoted as
synbiotics), which could favour the production of lactic acid
and butyrate. Such approaches may stimulate synergistic effects
of probiotics and the endogenous microbiota and their meta-
bolites, and could provide new scenarios to generate beneficial
health effects in IBS patients. This is of particular interest in the
light of the significant differences that have been reported for
the intestinal microbiota composition when comparing IBS
patients and healthy controls in both adult(172) and children(192)
cohorts. The role of butyrate is especially interesting in this
perspective, because it has been shown to alleviate the
perception of afferent visceral signalling and, as a consequence,
could improve IBS symptoms(193).
More research is also required to improve the colonisation of
probiotic bacteria, as well as to identify optimal duration and
possibly interruption of probiotic therapy in IBS. Moreover,
further work is needed to better understand the possible
interplay between probiotics and the endogenous microbiota,
which could affect IBS via various mechanistic scenarios.
Another important step forward would be targeting of carefully
characterised subpopulations on the basis of pathophysiology
rather than symptomatology, enabling a more personalised
approach in the future. In probiotic studies that target the IBS
population, a careful characterisation of alterations along the
microbe–gut–brain axis is highly recommended and may
support eventual probiotic therapies in IBS. Inversely, in view
of the importance of the microbe–gut–brain axis in IBS, it is
plausible that therapeutic option may also be found in the
improvement of certain aspects of brain function, including
mood, stress response and processing, with the aim to improve
symptoms in IBS patients, possibly by altering microbial com-
position and/or activity in the intestine.
Inflammatory bowel disease
IBD is the overall term used to describe 2 idiopathic inflam-
matory diseases of the gut, namely Crohn’s disease (CD) and
ulcerative colitis (UC). These diseases, however, are quite dif-
ferent. CD can affect any part of the bowel but predominantly
the terminal ileum and colon and is characterised by granulo-
matous, patchy, transmural mononuclear inflammation. In
contrast, UC only affects the colon and the lesions are mucosal
and continuous, with massive neutrophil infiltration, crypt
abscesses, loss of goblet cells and epithelial cell damage. There
is rather strong evidence that the immune response in CD is
directed against the indigenous microbiota, but in UC the role of
the microbiota is more contentious(194). In active IBD, mucosal
inflammation is accompanied by impaired barrier function(195).
The effect of inflammation on the barrier is likely to have many
components. Pro-inflammatory cytokines such as interferon-
γ(196) and TNF-α make the epithelium leaky(197). Cytokine IL-13
induces up-regulation of claudin 2, changing ion transport
across the epithelium(198). Matrix metalloproteinases such as
matrix metallopeptidase (MMP)-12 made by activated macro-
phages and MMP-3 made by activated myofibroblasts degrade
the epithelial basement membrane and disrupt epithelial cell
adhesion leading to anoikis(199). Free radicals and serine
proteinases made by neutrophils directly kill epithelial cells.
Many studies have evaluated the potential of probiotics to
contribute to IBD treatment. However, a fundamental problem
with these studies is that different probiotics were used, either
alone or in combination with other therapies. This makes the
case that probiotics might work in IBD, but so far, we have not
discovered the correct organism or combination of organisms.
One should also note that IBD diseases are very serious con-
ditions. For example, the induction of remission in CD requires
powerful immunosuppressive agents such as corticosteroids,
azathioprine and anti-TNF. In UC, the mainstay of remission
induction in active disease is also corticosteroids. In view of the
seriousness of these diseases, the idea that probiotics would be
useful in treating active IBD is rather fanciful. Instead, there is
much more of an opportunity to determine whether probiotics
can help in maintaining remission, where their effects on
maintaining the barrier are more relevant.
Three studies (with largely the same protocol) have investi-
gated whether probiotic therapy prevents endoscopic recur-
rence of CD after surgical resection. It is very well established
that recurrence of disease is first seen proximal to the anasto-
mosis after resection. Although different probiotics were used in
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each study, the conclusions reached in each were consistent,
indicating that no advantage was observed in the probiotic-
treated groups compared with the placebo controls(200–202).
Synbiotic therapies combine probiotics with prebiotics, and
although an initial synbiotic study did not report any benefit in
post-operative occurrence of CD(203), a more recent study
reported a slight but significant enhancement of the induction
of remission of active CD(204). Taken together, the use of
probiotics as a therapy for active CD or for maintenance of
disease remission has been disappointing, which has also been
concluded in various recent reviews(205,206). Notably, more
promising results have been obtained for the use of probiotics
in therapeutic applications to induce remission of UC, but also
for supporting the maintenance of UC remission(205). In a
double-blind study comparing mesalazine with an oral pre-
paration of viable E. coli strain Nissle (Serotype 06: K5: H1) with
regard to their efficacy in preventing a relapse of the disease
over a period of 12 weeks, probiotic treatment was equivalent
to mesalazine(207).
Pouchitis is an iatrogenic condition that occurs when a pouch
is formed from terminal ileum and anastomosed onto the
rectal stump following colectomy for UC, giving patients the
opportunity to live without a stoma. Most patients develop
some form of inflammation in the neo-reservoir (pouchitis).
Standard therapy is the use of antibiotics such as metronidazole
and ciprofloxacin. A number of studies in children and adults
have demonstrated that taking a mixture of probiotic strains
(VSL#3) is effective in preventing pouchitis and also can play a
significant role in treating active pouchitis(205). It is likely that
the efficacy of this probiotic preparation in pouchitis is due to
the highly unusual situation in the pouch that forms a reservoir
for ileal fluid, which could create an environment that allows
probiotics to competitively inhibit potential harmful bacteria
and fungi and thereby have its positive effects in pouchitis.
In terms of probiotic effects on the compromised epithelial
barrier function in IBD, they may be exerted by different prin-
cipal modes of action. First, probiotics may dampen mucosal
inflammation activity, thereby allowing the epithelial function to
return to normal. One intensively studied way to achieve
suppression of mucosal inflammation is through the modulation
of the balance and activity of the mucosal T-cell repertoire,
particularly focused on stimulation of the regulatory T-cell
populations(208). Second, and more important in the context of
this review, probiotics may directly affect the epithelial cells,
leading to restoration of mucosal barrier integrity, thereby
lowering the luminal antigenic stimulation that drives inflam-
mation and suppressing inflammatory responses.
Many in vitro studies have demonstrated that probiotics can
maintain the epithelial barrier and protect against cytokine-
driven epithelial barrier dysfunction. Work by Polk et al. has
taken this to a new level by isolating a P40 component
of L. rhamnosus GG, which prevents cytokine-induced epi-
thelial barrier dysfunction by signalling through the epidermal
growth factor receptor(209). When formulated for delivery into
the mouse gut, P40 ameliorates colitis induced by DSS. In the
same mouse model, a variety of studies highlights the potential
of single strain or mixtures of probiotics to thicken the mucus
layer and/or improve epithelial barrier function in general, with
beneficial consequences for the inflammation read-outs in these
animals(210–213). A soluble factor from Bifidobacterium infantis
also increases occludin and ZO-1 in epithelial cells in vitro and
ameliorates colitis in IL-10 knock-out mice(214,215). These data
have also been taken into humans where it has been shown
that L. plantarum perfusion in the duodenum, elicits structural
changes in ZO-1 and occludin complexes that correlate with
enhanced barrier function(25). These examples do not provide a
complete view of the available data, but there seems to be little
doubt that probiotics and probiotic components can influence
epithelial barrier integrity, and further molecular characterisation
may resolve how specific probiotic components can affect the
receptors and pathways they modulate. These insights could
reinforce the specific role of probiotics in the treatment of UC and
pouchitis, but is unlikely to change the perspective on effective
probiotic treatment or maintenance of remission in CD.
Concluding remarks
Intestinal barrier integrity is a hallmark of gut health and a
reflection of appropriate microbiota-accommodating homeo-
stasis of mucosal function, which is orchestrated to combine
maximised absorptive capacity with appropriate defensive
reactions against chemical and microbial challenges. Many
factors contribute to mucosal barrier function, including epi-
thelial integrity, which is protected by the mucus layer that
creates a physicochemical barrier that prevents direct contact of
luminal challenges with the epithelia and is further supported
by innate and adaptive immune functions. The endogenous
microbiota play a key role in establishing mucosal barrier
function development in infancy, but also in maintenance of
this function during later life(216).
The production of butyrate by the fermentative activity of
the microbiota has been reported to increase production of
secreted mucus and support regulatory T-cell functions in
the gut(217–219). Thus, modulation of the butyrate-producing
sub-consortia of microbiota through prebiotics or dietary fibre
supports the idea that nutritional strategies might also be
effective in enhancing epithelial barrier function.
A striking example of how microbiota modulation can have a
therapeutic effect is the use of faecal transplantation (bacterio-
therapy) to treat C. difficile-associated disease, which has been
successful even after the failure of multiple courses of anti-
biotics(220,221). With the growing success of faecal transplantation
for C. difficile, patients suffering from other intestinal diseases
such as IBD or the metabolic syndrome have been enrolled for
faecal transplantation. Indeed, recent studies on UC(222) and the
metabolic syndrome(223) indicated that gut microbiota infusion
improved remission period length or insulin resistance, respec-
tively, supporting the efficiency of gut microbiota transfer to
improve some microbiota-related pathologies. However, studies
on long-term efficiency of such microbiota transfer to elicit sus-
tained health benefits still need to be addressed. Notably, the
safety of the faecal material that is used for transplantation cannot
be entirely assessed, because of the complexity of the microbial
community. Consequently, there is an increasing interest in stra-
tegies aiming to define a well-characterised microbial cocktail of
selected intestinal microbes that can effectively deliver the same
100 P. A. Bron et al.
health-promoting functionality as faecal donations, and replace
faecal transplantation.
A compromised intestinal barrier is associated with several
human gut-related disorders, for example IBD, NEC and low-
grade inflammation associated with the metabolic syndrome
(obesity and diabetes). In addition, several other diseases also
appear to be associated with a ‘leaky’ gut phenotype, including
the post-infectious subtype of IBS(224), and possibly also
allergy(225). Several lines of evidence indicate that probiotics
can influence various aspects of intestinal barrier function (see
above), which would support their therapeutic potential in
diseases involving a dysfunctional gut barrier. However, most of
the probiotic barrier effects were studied in in vitro cell line and
animal models and the translation of these results to human
efficacy in vivo in at risk or diseased populations remain
virtually unexplored. Only very few studies using probiotics
have directly evaluated mucosal barrier function in human
volunteers, and in the studies where this parameter was
measured healthy volunteers rather than diseased populations
were typically targeted(25,26). Notably, both positive(144,226) and
negative(26,227) impacts of probiotic consumption on barrier
function have been reported, suggesting that a balanced view is
required to evaluate their capacity to modulate intestinal barrier
function in humans, particularly when severely compromised
patient groups are targeted. Importantly, in the attempt to trans-
late the results obtained in in vitro studies and experiments that
use inbred animals, one should take into account that (healthy as
well as diseased) humans are highly individual. Notably, it is
commonly seen that molecular responses elicited by dietary
interventions in humans are small in comparison with the differ-
ences observed between participating individuals per se. This
level of individuality has been captured in the ‘bandwidth of
health’ concept, which may explain the unpredictable distribu-
tions of responders and non-responders in nutritional intervention
trials(3,228). Therefore, high-resolution, molecular phenotyping of
dietary trial participants may offer new avenues to select sub-
groups of individuals predicted to be more responsive to the
molecular response elicited by the probiotic treatment, for
example, are predicted to benefit from a specific mechanism of
barrier function improvement. These avenues would evolve to a
more personalised nutrition approach and abandon the ‘one size
fits all’ concept that is used in most studies to date.
Despite the difficulties in translating in vitro and animal study
outcomes to human populations, a variety of studies imply that
mucosal barrier function can be improved by probiotic treat-
ment. This starting point underpins the need for studies in well-
diagnosed diseased populations (e.g. including high resolution
molecular profiling) where this health parameter is directly
assessed in a probiotic intervention regimen. The current
literature does not report this type of human studies, which may
provide pivotal scientific support for the health-promoting
therapeutic potential of probiotic treatment in disease, with a
plausible underlying mode of action.
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